Topical Imiquimod Treatment for Nodular Basal Cell Carcinomas: An Open-Label Series
Imiquimod has been used for basal cell carcinomas (BCCs). This is the first open-label series using imiquimod for nodular BCC with Mohs surgery resection for confirmation of treatment. Objective.
To evaluate the efficacy of topical imiquimod in patients with biopsy-proven nodular BCC. Results.
After 12 weeks for three times a week application, treatment sites at week 15 were surgically excised using Mohs micrographic surgery. All 15 treatment subjects were clear of BCC. At the 18-month follow-up, no patients had recurrent tumor. Conclusion.
Imiquimod 5% cream may be another treatment modality for nodular BCC.
DRS. RAYMOND T. KUWAHARA, RAASHID HAQUE, AND ROBERT B. SKINNER, JR. ARE CONSULTANTS FOR 3M PHARMACEUTICALS.
Document Type: Research Article
Publication date: 2004-03-01